Ipca Laboratories Limited
NSE: IPCALAB BSE: IPCALAB
NSE
1,370.90
-15.10 (-1.09%)
Prev Close
1386
Open Price
1388
Volume
594,702
Today Low / High
1361 / 1393.7
52 WK Low / High
1052 / 1755.9
Range
1,302 - 1,439
BSE
1,370.05
-16.80 (-1.21%)
Prev Close
1386.85
Open Price
1387
Volume
7,179
Today Low / High
1365 / 1392
52 WK Low / High
1060.95 / 1757.65
Range
1,302 - 1,439
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1370.9 (target range: 1,302 - 1,439), reflecting a change of -15.1 (-1.08947%). On the BSE, it is listed at 1370.05 (target range: 1,302 - 1,439), showing a change of -16.8 (-1.21138%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
1,388.00
-1.23%
05 Jun
1,394.00
-0.57%
04 Jun
1,401.00
-0.36%
03 Jun
1,416.00
-1.12%
02 Jun
1,428.00
-0.85%
30 May
1,483.10
-3.93%
29 May
1,503.00
-2.20%
28 May
1,459.80
2.40%
27 May
1,478.00
-1.24%
26 May
1,469.80
-0.28%
23 May
1,450.90
0.63%
22 May
1,477.40
-2.34%
21 May
1,466.60
0.32%
20 May
1,442.80
1.00%
19 May
1,402.00
2.48%
16 May
1,414.50
-1.55%
15 May
1,415.30
-0.64%
14 May
1,404.20
1.01%
13 May
1,371.80
2.36%
12 May
1,386.80
-1.10%
09 May
1,333.00
2.16%
Ipca Laboratories Limited Graph
Ipca Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Ipca Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,370.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,370.05 | 1,383.75 | 1,245.38 - 1,522.13 |
| 1,397.45 | 1,117.96 - 1,676.94 | ||
| 1,411.15 | 987.81 - 1,834.50 | ||
| Bearish Scenario | 1,370.05 | 1,356.35 | 1,220.71 - 1,491.98 |
| 1,342.65 | 1,074.12 - 1,611.18 | ||
| 1,328.95 | 930.26 - 1,727.63 |
Overview of Ipca Laboratories Limited
ISIN
INE571A01038
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
262,019
Market Cap
347,802,813,600
Last Dividend
4
Official Website
IPO Date
1996-01-01
DCF Diff
-1,693.64
DCF
3,065
Financial Ratios Every Investor Needs
Stock Dividend of IPCALAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-05 | August 05, 25 | 2 | 2 | 2025-08-05 | 2025-09-01 | |
| 2024-11-27 | November 27, 24 | 2 | 2 | 2024-11-27 | 2024-12-10 | |
| 2024-08-06 | August 06, 24 | 2 | 2 | 2024-08-06 | 2024-09-10 | |
| 2023-11-22 | November 22, 23 | 2 | 2 | 2023-11-22 | 2023-12-10 | |
| 2022-11-22 | November 22, 22 | 4 | 4 | 2022-11-23 | 2022-12-07 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 7,622.41 Cr | 2,847.47 Cr | 4,774.94 Cr | 0.6264 | 170.71 Cr | 117.40 Cr | 2,959.65 Cr | 547.35 Cr | 21.57 | 1,329.95 Cr | 0.0718 |
| 2023-03-31 | 6,244.32 Cr | 2,407.51 Cr | 3,836.81 Cr | 0.6144 | 130.76 Cr | 76.19 Cr | 703.35 Cr | 471.32 Cr | 18.58 | 1,052.66 Cr | 0.0755 |
| 2022-03-31 | 5,766.46 Cr | 2,105.97 Cr | 3,660.49 Cr | 0.6348 | 41.79 Cr | 73.65 Cr | 1,062.66 Cr | 884.08 Cr | 34.85 | 1,378.34 Cr | 0.1533 |
| 2021-03-31 | 5,420.73 Cr | 1,801.76 Cr | 3,618.97 Cr | 0.6676 | 121.35 Cr | 97.07 Cr | 1,314.59 Cr | 1,140.01 Cr | 45.01 | 1,609.40 Cr | 0.2103 |
| 2020-03-31 | 4,558.70 Cr | 3,209.28 Cr | 1,349.42 Cr | 0.2960 | 96.45 Cr | 58.58 Cr | 744.67 Cr | 606.32 Cr | 24.00 | 965.23 Cr | 0.1330 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 208.91 Cr | 11,101.28 Cr | 3,374.28 Cr | 6,332.1900 Cr | 1,438.36 Cr | 1,229.45 Cr | 2,469.56 Cr | 4,696.18 Cr | 16.87 Cr | 0.12 Cr | 303.61 Cr | 2,355.6400 Cr |
| 2023-03-31 | 1,257.85 Cr | 8,626.43 Cr | 2,711.11 Cr | 5,842.0200 Cr | 1,481.27 Cr | 223.42 Cr | 1,743.37 Cr | 2,694.58 Cr | 27.40 Cr | 0.28 Cr | 302.66 Cr | 1,805.8200 Cr |
| 2022-03-31 | 275.19 Cr | 7,623.53 Cr | 2,081.77 Cr | 5,491.8700 Cr | 807.22 Cr | 532.03 Cr | 1,857.97 Cr | 2,502.59 Cr | 26.77 Cr | 0.54 Cr | 269.88 Cr | 1,465.8800 Cr |
| 2021-03-31 | 165.97 Cr | 6,068.36 Cr | 1,352.18 Cr | 4,701.6500 Cr | 265.39 Cr | 99.42 Cr | 1,594.81 Cr | 2,146.45 Cr | 20.85 Cr | 0.59 Cr | 111.43 Cr | 1,160.5400 Cr |
| 2020-03-31 | 58.46 Cr | 5,259.83 Cr | 1,618.72 Cr | 3,627.4800 Cr | 500.72 Cr | 442.26 Cr | 1,323.12 Cr | 1,993.25 Cr | 118.40 Cr | 0.70 Cr | 71.31 Cr | 1,326.4200 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 944.6500 Cr | -1,291.7900 Cr | -552.5500 Cr | 533.3600 Cr | -823.1900 Cr | 755.7900 Cr | -410.6000 Cr | 547.3500 Cr | -356.8800 Cr | -50.7400 Cr | -92.9500 Cr |
| 2023-03-31 | 805.8100 Cr | -725.0000 Cr | 507.2400 Cr | 311.3400 Cr | 588.0500 Cr | 1,578.9800 Cr | -494.4700 Cr | 745.2900 Cr | 657.7100 Cr | -101.4800 Cr | 114.6000 Cr |
| 2022-03-31 | 856.0400 Cr | -855.0500 Cr | 426.7800 Cr | 377.1200 Cr | 431.9200 Cr | 990.9300 Cr | -478.9500 Cr | 1,135.7200 Cr | 540.3200 Cr | -101.4800 Cr | -249.1500 Cr |
| 2021-03-31 | 1,090.1300 Cr | -520.6900 Cr | -305.8200 Cr | 728.5800 Cr | 263.6200 Cr | 559.0100 Cr | -361.5500 Cr | 1,381.2800 Cr | -225.7900 Cr | -101.5300 Cr | -271.6900 Cr |
| 2020-03-31 | 570.3500 Cr | -509.6500 Cr | -136.5400 Cr | 264.0700 Cr | -75.5300 Cr | 295.3900 Cr | -306.2800 Cr | 738.8900 Cr | -6.3100 Cr | -121.6600 Cr | -239.8600 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 2,245.37 Cr | 668.21 Cr | 1,577.16 Cr | 0.7024 | 364.62 Cr | 248.14 Cr | 9.78 | 483.19 Cr | 0.1105 |
| 2024-09-30 | 2,354.90 Cr | 758.56 Cr | 1,596.34 Cr | 0.6779 | 341.13 Cr | 229.48 Cr | 9.05 | 467.74 Cr | 0.0974 |
| 2024-06-30 | 2,092.63 Cr | 643.49 Cr | 1,449.14 Cr | 0.6925 | 293.83 Cr | 192.24 Cr | 7.58 | 413.33 Cr | 0.0919 |
| 2024-03-31 | 2,033.01 Cr | 1,250.03 Cr | 782.98 Cr | 0.3851 | 98.15 Cr | 59.59 Cr | 2.35 | 204.10 Cr | 0.0293 |
| 2023-12-31 | 2,052.86 Cr | 696.95 Cr | 1,355.91 Cr | 0.6605 | 254.28 Cr | 179.88 Cr | 7.09 | 421.79 Cr | 0.0876 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 255.94 Cr | 688.69 Cr | 944.63 Cr | 0.00 Cr | 2,518.31 Cr | 5,680.69 Cr | 4,776.43 Cr | 11,423.77 Cr | 3,306.11 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 854.26 Cr | 0.00 Cr | 0.00 Cr | 854.26 Cr | 0.00 Cr | 0.00 Cr | -7,727.00 Cr |
| 2024-03-31 | 208.91 Cr | 636.44 Cr | 845.35 Cr | 1,694.61 Cr | 2,469.56 Cr | 5,538.90 Cr | 4,663.10 Cr | 11,101.28 Cr | 3,374.28 Cr |
| 2023-12-31 | -934.07 Cr | 1,868.14 Cr | 934.07 Cr | 0.00 Cr | 0.00 Cr | 934.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 433.93 Cr | 435.30 Cr | 934.07 Cr | 1,760.01 Cr | 2,450.25 Cr | 5,719.61 Cr | 4,608.30 Cr | 11,383.80 Cr | 3,822.99 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 192.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 59.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 179.88 Cr | 199.00 Cr | 0.00 Cr | 0.00 Cr | 199.00 Cr | 697.77 Cr | 498.77 Cr | 0.00 Cr | 199.00 Cr |
| 2023-09-30 | 145.06 Cr | 180.68 Cr | 0.00 Cr | 0.00 Cr | 180.68 Cr | 498.77 Cr | 318.09 Cr | 0.00 Cr | 180.68 Cr |
| 2023-06-30 | 162.82 Cr | 138.54 Cr | 0.00 Cr | 0.00 Cr | 138.54 Cr | 1,397.79 Cr | 1,259.25 Cr | 0.00 Cr | 138.54 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2022-01-10 | January 10, 22 | 2:1 |
| 2010-03-22 | March 22, 10 | 5:1 |
| 2005-01-28 | January 28, 05 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
President of Marketing
Mr. Sunil Ghai
Gender: male
Year Born: 1963
President of Human Resources
Mr. Saidutta Nanda
Gender: male
Year Born:
Chief Executive Officer, MD & Executive Director
Mr. Pranay Premchand Godha
Gender: male
Year Born: 1972
Compliance Officer, Corporate Counsel & Company Secretary
Mr. Harish Pandurang Kamath
Gender: male
Year Born: 1959
Vice President of Operations
Mr. Pawan Kothari
Gender: male
Year Born: 1965
Vice President of Technical
Mr. Vishnu Saran Singh Kushwaha
Gender: male
Year Born: 1968
President of R&D - Chemicals
Dr. Ashok Kumar
Gender: Not Specified
Year Born: 1954
Executive Director
Mr. Prashant Premchand Godha
Gender: male
Year Born: 1975
Executive Chairman
Mr. Premchand Godha A.C. A., B. Com., CA
Gender: male
Year Born: 1946
Chief Financial Officer, MD & Executive Director
Mr. Ajit Kumar Bhanwarlal Jain A.C.A., B.Sc.
Gender: male
Year Born: 1955
FAQs about Ipca Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Pranay Premchand Godha.
What is the current market price of the stock?
The current price is ₹1,370.90.
What is the 52-week price range?
The range is ₹1052-1755.9.
What is the market capitalization of the company?
The market capitalization is ₹34,780.28 crores.
What is the dividend yield?
The dividend yield is 0.29%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 47.68.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Ipca Laboratories Limited (ISIN: INE571A01038) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹34,780.28 crores and an average daily volume of 262,019 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.